The biggest losers of the session on the Wall Street include CTI BioPharma Corp. (NASDAQ:CTIC), which fell -0.04 points or -4.76% to trade at $0.8 as last check. The stock closed last session at $0.84 and sets an active trading volume day with a reported 137223 contracts so far this session. CTIC shares had a relatively better volume day versus average trading capacity of 275.1 thousand shares, but with a 57.54 million float and a -7.9% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for CTIC stock indicates that the average analyst price target is $5.33 per share. This means the stock has a potential increase of 566.25% from where the CTIC share price has been trading recently which is between $0.82 and $0.8745. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $4.
The shorts are climbing into CTI BioPharma Corp. (CTIC) stock. The latest set of short interest data was released on 30 April 2019, and the numbers show a rise in short interest in CTIC shares. While short interest still represents only 2.71% of CTIC’s float, the number of shares shorted have risen by 128036. The number of shares shorted advanced to 1686849 shares, up from 1558813 shares during the preceding fortnight. With average daily trading volumes at 220995 shares, days to cover increased to about 6.80143 days. The most recent news story about the stock that appeared in Yahoo Finance‘s news section was titled “CTI BioPharma: 1Q Earnings Snapshot” and dated May 02, 2019.
During the recent trading session for CTI BioPharma Corp. (NASDAQ:CTIC), the company witnessed their stock drop by $-0.11 over a week and tumble down $-0.16 from the price 20 days ago. When compared to their established 52-week high of $5.36, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 06/27/18. The recent low of $0.6 stood for a -85.05% since 12/24/18, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.57 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to.
Looking at the current readings for CTI BioPharma Corp., the two-week RSI stands at 26.71. This figure suggests that CTIC stock, for now, is overbought, meaning that the shares are not stable in terms of price movement. The stochastic readings, on the other hand, based on the current CTIC readings is similarly very revealing as it has a stochastic reading of 22.95% at this stage. This figure means that CTIC share price today is being overbought.
Technical chart claims that CTI BioPharma Corp. (CTIC) would settle between $0.87/share to $0.9/share level. However, if the stock price goes below the $0.82 mark, then the market for CTI BioPharma Corp. becomes much weaker. If that happens, the stock price might even plunge as low as $0.79 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.05. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at Lake Street, assumed coverage of CTIC assigning Buy rating, according to their opinion released on March 05. Needham, analysts launched coverage of CTI BioPharma Corp. (NASDAQ:CTIC) stock with a Buy recommendation, according to their flash note issued to investors on March 26. Analysts at JMP Securities, made their first call for the equity with a Mkt Outperform recommendation, according to a research note that dated back to March 07.
CTIC equity has an average rating of 2, with the figure leaning towards a bullish end. 3 analysts who tracked the company were contacted by Reuters. Amongst them, 0 rated the stock as a hold while the remaining 3 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 3 analysts rated CTI BioPharma Corp. (NASDAQ:CTIC) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Moving on, CTIC stock price is currently trading at 0X forward 12-month Consensus EPS estimates, and its P/S ratio is 3.86 while for the average stock in the same group, the multiple is 49.5.